Ocular Toxicities of Epidermal Growth Factor Receptor Inhibitors and Their Management
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Oncology(nursing),Oncology
Reference15 articles.
1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.;Cunningham;N Engl J Med,2004
2. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.;Saltz;J Clin Oncol,2004
3. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.;Ranson;J Clin Oncol,2002
4. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.;Baselga;J Clin Oncol,2002
5. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.;Perez-Soler;J Clin Oncol,2004
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors;Oncology and Therapy;2022-12-21
2. Ocular adverse effects of therapeutic biologics;Therapeutic Advances in Ophthalmology;2022-01
3. Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases;Journal Français d'Ophtalmologie;2021-01
4. Immune-Related Oral, Otologic, and Ocular Adverse Events;Advances in Experimental Medicine and Biology;2021
5. Oncolytic Drugs;Drug-Induced Ocular Side Effects;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3